Hermann Hauser
Hermann co-founded Amadeus Capital Partners in 1997 with Anne Glover. In his long and successful history as an entrepreneur and venture capitalist, Hermann has founded or co-founded companies in a wide range of technology sectors. These include Acorn Computers (where he helped spin out ARM), Active Book Company, Virata, Net Products, NetChannel and Cambridge Network. He was a founder director of IQ (Bio), IXI Limited, Vocalis, SynGenix, Advanced Displays Limited, acquired by Cambridge Display Technology, Electronic Share Information Limited, E*Trade UK and has supported many other start-ups.
Hermann’s successes at Amadeus include CSR plc (LON: CSR); Entropic Research Laboratory, acquired by Microsoft in 1999; Solexa, acquired by Illumina in 2007 and Icera, acquired by Nvidia in 2011. He is currently a non-executive director of XMOS and is the Amadeus representative at Graphcore, the creators of the Intelligence Processing Unit (IPU), a processor specifically designed for artificial intelligence.
Hermann holds an MA in Physics from Vienna University and a PhD in Physics from the University of Cambridge. He is a Fellow of the Institute of Physics and of the Royal Academy of Engineering, and an Honorary Fellow of King’s College, Cambridge. Hermann holds honorary doctorates from the Universities of Bath, Loughborough, Anglia Ruskin. Strathclyde, Glasgow and York and was awarded an Honorary CBE for ‘innovative service to the UK enterprise sector’ in 2001.
In 2004, he was made a member of the Government’s Council for Science & Technology. In 2012 he became a Fellow of the Royal Society in recognition of his contribution to the translation of science into business and in 2013 a Distinguished Fellow of BCS, the Chartered Institute for IT. In 2015 he was made an Honorary Knight Commander of the Most Excellent Order of the British Empire (KBE) for services to engineering and industry and was made a Fellow of the Royal Society of Chemistry.
Amadeus Capital
CEO Luncheon – Navigating Today’s Economic Challenges: Leading Through Uncertainty
-
In a time marked by market volatility, capital constraints, and shifting global priorities, what strategies are biotech and deep tech CEOs adopting to survive—and thrive? Join a candid, invite-only conversation with leading venture capitalists and investment bankers as they share their perspectives on the current economic landscape, investor expectations, and how companies can position themselves for resilience and growth. This luncheon offers a unique opportunity for peer connection, grounded insights, and actionable guidance on navigating today’s toughest financial headwinds.
Funding Early Stage Biotech to Fuel the Endless Frontier
-
In this conversation, we explore the dynamic interplay between public funding and private investment in shaping the next wave of biotechnology breakthroughs and safeguarding regional technology sovereignty. We’ll examine how government agencies fund high-risk, high-reward early-stage research, why America and China have staked their claims in biotechnology leadership, and what Europe must do to forge its own independent capabilities. The discussion will also highlight the critical role of the private sector—from strategic venture investments in sequencing and diagnostics to innovative startup ventures—and the policy frameworks necessary to sustain a vibrant, self-reliant bioinnovation ecosystem.